Sunnyvale, Calif., August 10, 2026
Ceribell, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for two new artificial intelligence-powered algorithm enhancements integrated into its cloud-based Neurology Portal. The new Epileptiform Abnormality Detection and Artifact Reduction capabilities expand the clinical utility of the company’s Ceribell Point-of-Care (POC) brain monitoring system, providing neurologists and bedside clinicians with additional tools for rapid electroencephalogram (EEG) assessment. The enhancements are designed to address common challenges in critical-care EEG interpretation, including interference caused by patient movement, medical equipment and other physiological signals, as well as lengthy recordings containing complex abnormal brain activity. Ceribell said the new technology is intended to provide clinicians with a more organized and efficient starting point for reviewing continuous EEG recordings in emergency departments and intensive care units.
AI Algorithm Targets EEG Artifacts and Abnormalities
Ceribell’s new Artifact Reduction algorithm is designed to help clinicians distinguish cerebral signals from non-cerebral interference commonly encountered during critical-care EEG monitoring. Artifacts can originate from nearby medical equipment, patient movement and physiological signals, potentially making EEG interpretation more difficult and time-consuming. According to Ceribell, the new AI algorithm goes beyond conventional filtering approaches by recognizing different types of artifacts using training from the company’s extensive real-world artifact dataset. The second enhancement, Epileptiform Abnormality Detection, is designed to identify and flag abnormal epileptiform patterns within lengthy EEG recordings. Critical-care EEGs do not always present a simple distinction between seizure and no seizure, with many recordings showing patterns along the ictal-interictal continuum. By highlighting these abnormalities directly within the recording viewer, the technology is designed to help neurologists focus their attention on potentially important sections of an EEG rather than manually reviewing hours of raw data.
Ceribell Platform Uses More Than One Million EEG Hours
The latest Neurology Portal enhancements build on Ceribell’s broader AI-powered neuromonitoring platform, which combines portable EEG hardware with software designed for rapid deployment in acute-care environments. Ceribell said its algorithms are supported by a database containing more than one million hours of EEG data, providing a substantial foundation for continued development of its AI capabilities. The company’s point-of-care system is designed to reduce the time required to initiate bedside EEG monitoring, with monitoring able to begin in as little as five minutes. The new software enhancements are designed to integrate into existing clinical workflows without requiring software downtime or installation. This approach could help hospitals and neurologists incorporate additional AI-assisted analysis into existing EEG review processes while maintaining rapid access to continuous brain monitoring in settings where timely neurological assessment can be critical..
Advertisement
FDA Clearance Expands Critical-Care Neurology Capabilities
The FDA clearance represents another development in Ceribell’s strategy to use artificial intelligence and point-of-care EEG technology to improve the diagnosis and management of serious neurological conditions. By combining automated identification of epileptiform abnormalities with improved artifact reduction, the company aims to provide clinicians with clearer EEG recordings and more efficient review workflows. Ceribell said the enhancements were developed in response to real-world feedback from clinical users, with the goal of improving diagnostic confidence and reducing the operational burden associated with continuous EEG interpretation. The company’s existing Ceribell System is FDA-cleared for use in detecting seizure and delirium in intensive care units and emergency rooms across the United States. The newly cleared capabilities add further AI functionality to the platform and could strengthen its role in critical-care neuromonitoring, where rapid interpretation of complex neurological data can influence clinical decision-making. The development highlights the growing application of AI in medical devices and neurological diagnostics, particularly in environments requiring rapid analysis of high-volume clinical data.
Source: Ceribell press release
